Publicaciones en colaboración con investigadores/as de Hospital del Mar (71)

2024

  1. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 72-78

  2. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  3. Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus

    Reumatologia Clinica, Vol. 20, Núm. 6, pp. 312-319

  4. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice

    Reumatologia Clinica, Vol. 20, Núm. 1, pp. 24-31

  5. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  3. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

    Frontiers in Immunology, Vol. 14

  4. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

  5. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register

    RMD Open, Vol. 8, Núm. 2

  3. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review

    Seminars in Arthritis and Rheumatism, Vol. 52

  4. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  5. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

    eBioMedicine, Vol. 80

  6. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

  7. Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment

    Expert Opinion on Biological Therapy, Vol. 22, Núm. 7, pp. 821-829

2021

  1. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

  2. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  3. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

    BMC Musculoskeletal Disorders, Vol. 22, Núm. 1